

Curriculum Vitae
Michael Due Larsen,
Associate Professor, PhD. M.Sc. Pharm,

PERSONAL INFORMATION

Date of birth: 30 March 1973, Randers, Denmark
Citizenship: Danish
E-mail: NTNU: michael.d.larsen@ntnu.no • OUH: michael.due.larsen@rsyd.dk
URL: www.ntnu.no/ansatte/michael.d.larsen
Phone: NTNU: +47 949 80 508 • OUH: +45 2678 7472
Address (home): Nils Stavnes veg 6, 7019 Trondheim

EDUCATION

2014 PhD, University of Southern Denmark
2000 MSc pharmacy, The Royal Danish School of Pharmacy

PROFESISONAL APPOINTMENTS

2021 - Deputy leader for education, Department of Clinical and Molecular Medicine
2019 - Associate Professor,
Department of Clinical and Molecular Medicine
Faculty of Medicine and Health Sciences,
Norwegian University of Science and Technology, Trondheim Norway
2019 - Affiliated researcher
Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark
2013 - 2019 Epidemiology - research - data management.
Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark
2015 –2019 Associate Professor
Department of Clinical Research, University of Southern Denmark
2007 – 2013 Assistant Head of Study Board, Pharmacy Education, University of Southern
Denmark
2006 Jan. Clinical Pharmacist, Dep. Biochemistry, Pharmacology, Genetics, Odense
University Hospital
2004 Nov. Clinical Pharmacist, Hospital of Viborg, Denmark
2002 Mar. Manager, Hospital Pharmacy, Queen Ingrid's Hospital, Nuuk, Greenland
2001 Feb. Clinical Pharmacist, Hospital Pharmacy, Næstved, Denmark
2000 Sep. Pharmacist, Gl. Kongevej Pharmacy, Copenhagen, Denmark

PHD THESIS

Continuation of Drug Treatment across Primary and Secondary Care.

Three Pharmacoepidemiological Studies Based on Linkage of a Pharmacy Prescription Register and a Newly Established Inpatient Prescription Database.

University of Southern Denmark. January 2014.

PUBLICATIONS

Michael Due Larsen og Espen Skarstein Kolberg (red.) Kasuistikker i klinisk farmasi, Resonnementer og oppgaver i praksis, Fagboklaget, 1st ed. Oslo May 2023

ISBN: 9788245040135

<https://www.fagbokforlaget.no/Kasuistikker-i-klinisk-farmasi/I9788245040135>

Scientific research papers

Number of citations according to Scopus: 607. H-index: 15, ORCID: 0000-0002-0623-2481

1. Lund K, Zegers FD, Nielsen J, Brodersen JB, Knudsen T, Jens Kjeldsen, **Larsen MD**, Nørgård BM, Inflammatory Bowel Disease in Adults and Elderly: The Use of Selected Non-IBD Medication Examined in a Nationwide Cohort Study, Inflammatory Bowel Diseases, 2023 <https://doi.org/10.1093/ibd/izad244>
2. Lund K, Garvik OS, Aagaard SM, Jølving LR, **Larsen MD**, Damkier P, Nørgård BM. Paternal preconception exposure to non-steroid anti-inflammatory drugs or opioids and adverse birth outcomes: A nationwide registry-based cohort study. Andrology. 2023 Nov 8. doi: 10.1111/andr.13551.
3. Lund K, Zegers FD, Nielsen J, Brodersen JB, Knudsen T, Jens Kjeldsen, **Larsen MD**, Nørgård BM, Inflammatory Bowel Disease in Adults and Elderly: The Use of Selected Non-IBD Medication Examined in a Nationwide Cohort Study, Inflammatory Bowel Diseases, 2023 <https://doi.org/10.1093/ibd/izad244>
4. Lund K, **Larsen MD**, Knudsen T, Kjeldsen J, Nielsen RG, Mertz Nørgård B, Brage S. Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease. BMC Gastroenterol. 2022 Jun 7;22(1):290
5. Winter RW, Friedman S, Nielsen J, Kjeldsen J, Nørgård BM, **Larsen MD**. Infliximab is not associated with a general long-term weight gain in patients with inflammatory bowel disease: a nationwide study. Am J Gastroenterol. 2022 May 1;117(5):777-784. (*Impact factor 4.7*)
6. **Larsen MD**, Nørgård BM, Kjeldsen J. Does Disease Activity after Induction Treatment with Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis. Jan 2022 (*Impact factor 5.3*)
7. Nørgård BM, Wod M, **Larsen MD**, Friedman S, Jølving LR, Fedder J. The impact of medical therapies and factors related to treatment procedures in women with rheumatoid arthritis and inflammatory bowel disease receiving assisted reproduction: a nationwide cohort study. Fertil Steril. 2021. (*Impact factor 6.3*)

8. Jølving LR, Erb K, Nørgård BM, Fedder J, **Larsen MD**. The Danish National Register of assisted reproductive technology: content and research potentials. *European journal of epidemiology*. 2021;36(4):445-52. (*Impact factor 7.1*)
9. Nørgård BM, Catalini L, Jølving LR, **Larsen MD**, Friedman S, Fedder J. The Efficacy of Assisted Reproduction in Women with a Wide Spectrum of Chronic Diseases - A Review. *Clinical epidemiology*. 2021;13:477-500. (*Impact factor 4.8*)
10. Lund K, **Larsen MD**, Knudsen T, Kjeldsen J, Nielsen RG, Mertz Nørgård B. Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study. *Journal of Crohn's & colitis*. 2021;15(4):575-82. (*Impact factor 7.8*)
11. Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, **Larsen MD**, Lund, K, Nørgård BM. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. *Journal of autoimmunity*. 2021;120:102632 (*Impact factor 7.6*)
12. Weltz V, Guldberg R, **Larsen MD**, Lose G. Body mass index influences the risk of reoperation after first-time surgery for pelvic organ prolapse. A Danish cohort study, 2010-2016. *International Urogynecology Journal*, 2021, 32(4), pp. 801–808.
13. Nørgård BM, Nielsen J, Knudsen T, Knudsen T, Nielsen RG, **Larsen MD**, Jølving LR, Kjeldsen J. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. *Br J Clin Pharmacol*. 2020;1–10. (*Impact factor 3.9*)
14. **Larsen MD**, Jensen DM, Fedder J, Jølving LR, Nørgård BM. Live-born children after assisted reproduction in women with type 1 diabetes and type 2 diabetes: a nationwide cohort study. *Diabetologia*. 2020;63(9):1736-44. (*Impact factor 7.5*)
15. **Larsen MD**, Jølving LR, Fedder J, Nørgård BM. The efficacy of assisted reproductive treatment in women with epilepsy. *Reprod Biomed Online*. 2020. (*Impact factor 2.9*)
16. Husby KR, **Larsen MD**, Lose G, Klarskov N. Surgical repair of vaginal vault prolapse; a comparison between ipsilateral uterosacral ligament suspension and sacrospinous ligament fixation-a nationwide cohort study. *International urogynecology journal*. 2020 (*Impact factor 2.1*)
17. Jølving LR, **Larsen MD**, Fedder J, Nørgård BM. Live birth in women with multiple sclerosis receiving assisted reproduction. *Reprod Biomed Online*. 2020;40(5):711-8. (*Impact factor 2.9*)
18. Nørgård BM, **Larsen MD**, Friedman S, Fedder J. Corticosteroids Prior to Embryo Transfer in Assisted Reproduction in Women with Crohn's Disease and Ulcerative Colitis - A Nationwide Cohort Study. *Clinical epidemiology*. 2020;12:317-26. (*Impact factor 4.6*)
19. Jølving LR, **Larsen MD**, Fedder J, Friedman S, Nørgård BM. The chance of a live birth after assisted reproduction in women with thyroid disorders. *Clin Epidemiol*. 2019;11:683-94. (*Impact factor 2.9*)
20. Lund K, **Larsen MD**, Knudsen T, Kjeldsen J, Nielsen RG, Nørgård BM. The impact of anti-TNFalpha therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015. *Aliment Pharmacol Ther*. 2019;50(10):1077-85. (*Impact factor 7.7*)

21. Husby KR, **Larsen MD**, Lose G, Klarskov N. Surgical treatment of primary uterine prolapse: a comparison of vaginal native tissue surgical techniques. International urogynecology journal. 2019. (*Impact factor 2.1*)
22. Korzenik J, **Larsen MD**, Nielsen J, Kjeldsen J, Norgard BM. Editorial: anti-TNF therapy-a double-edged sword? Authors' reply. Aliment Pharmacol Ther. 2019;50(7):823-4.
23. Korzenik J, **Larsen MD**, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti TNF α agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;00:1-6. (*Impact factor 7.7*)
24. Norgard BM, **Larsen MD**, Friedman S, Knudsen T, Fedder J. Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Annals of the rheumatic diseases. 2019;78(3):328-34. (*Impact factor 12.3*)
25. Norgard BM, Jolving LR, **Larsen MD**, Friedman S. Parental IBD and Long-term Health Outcomes in the Offspring. Inflamm Bowel Dis. 2019;25(8):1339-48 (*Impact factor 4.3*)
26. **Larsen MD**, Guldberg R, Lose G. Perioperative cardiovascular complications following urogynecological operations. Acta obstetrica et gynecologica Scandinavica. 2019;98(1):61-7.
27. Strehlau AG, **Larsen MD**, Sondergaard J, Almarsdottir AB, Rosholm JU. General practitioners' continuation and acceptance of medication changes at sectorial transitions of geriatric patients - a qualitative interview study. BMC family practice. 2018;19(1):168.
28. Friedman S, Magnussen B, O'Toole A, Fedder J, **Larsen MD**, Norgard BM. Increased Use of Medications for Erectile Dysfunction in Men With Ulcerative Colitis and Crohn's Disease Compared to Men Without Inflammatory Bowel Disease: A Nationwide Cohort Study. The American journal of gastroenterology. 2018. (*Impact factor 10.2*)
29. Weltz V, Guldberg R, **Larsen MD**, Magnussen B, Lose G. Influence of body mass index on short-term subjective improvement and risk of reoperation after mid-urethral sling surgery. International urogynecology journal. 2018;29(4):585-591.
30. **Larsen MD**, Friedman S, Magnussen B, Norgard BM. Birth Outcomes of Children Fathered by Men Treated with Systemic Corticosteroids during the Conception Period - A Cohort Study based on Nationwide Data. Basic Clin Pharmacol Toxicol. 2017.
31. Norgard BM, Magnussen B, **Larsen MD**, Friedman S. Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study. Gut. 2017;66(10):1761-6. (*Impact factor 17.0*)
32. Friedman S, **Larsen MD**, Magnussen B, Jolving LR, de Silva P, Norgard BM. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study. Reprod Toxicol. 2017;73:196-200.
33. Winter RW, **Larsen MD**, Magnussen B, Friedman S, Kammerlander H, Norgard BM. Birth Outcomes after Preconception Paternal Exposure to Methotrexate: A Nationwide Cohort Study. Reprod Toxicol. 2017
34. **Larsen MD**, Friedman S, Magnussen B, Norgard BM. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-alpha Agents Before Conception. The American journal of gastroenterology. 2016;111(11):1608-13. (*Impact factor 9.5*)

35. **Larsen MD**, Lose G, Guldberg R, Gradel KO. Discrepancies between patient-reported outcome measures when assessing urinary incontinence or pelvic-prolapse surgery. *International urogynecology journal*. 2016;27(4):537-43.
36. Norgard BM, Larsen PV, Fedder J, de Silva PS, **Larsen MD**, Friedman S. Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease receiving assisted reproduction: a 20-year nationwide cohort study. *Gut*. 2016;65(5):767-76. (*Impact factor 16.6*)
37. **Larsen MD**, Baldal ME, Nielsen RG, Nielsen J, Lund K, Norgard BM. The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data. *Scandinavian journal of gastroenterology*. 2016;51(9):1100-5.
38. Larsen L, Jensen MD, **Larsen MD**, Nielsen RG, Thorsgaard N, Vind I, et al. The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease. *Clinical epidemiology*. 2016;8:607-12.
39. Hansen UD, Gradel KO, **Larsen MD**. Danish Urogynaecological Database. *Clinical epidemiology*. 2016;8:709-12.
40. Kjeldsen J, Nielsen J, **Larsen MD**, Qvist N, Norgard BM. Postoperative Use of Anti-TNF-alpha Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study. *Inflammatory bowel diseases*. 2016;22(3):599-606.
41. **Larsen MD**, Qvist N, Nielsen J, Kjeldsen J, Nielsen RG, Norgard BM. Use of Anti-TNFalpha Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease. *Journal of Crohn's & colitis*. 2016;10(6):650-6.
42. **Larsen MD**, Rosholm JU, Hallas J. The influence of comprehensive geriatric assessment on drug therapy in elderly patients. *European journal of clinical pharmacology*. 2014;70(2):233-9.
43. **Larsen MD**, Schou M, Kristiansen AS, Hallas J. The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care. *European journal of clinical pharmacology*. 2014;70(7):859-65.
44. Pottegard A, Bjerregaard BK, **Larsen MD**, Larsen KS, Hallas J, Knop FK, et al. Use of exenatide and liraglutide in Denmark: a drug utilization study. *European journal of clinical pharmacology*. 2014;70(2):205-14.
45. Pottegard A, Poulsen BK, **Larsen MD**, Hallas J. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. *Journal of thrombosis and haemostasis*. 2014;12(9):1413-8.
46. **Larsen MD**, Hallas J. Hospital physicians' influence on gastrointestinal protection during treatment with non-steroidal anti-inflammatory drugs and acetylsalicylic acid and the impact on prescribing in primary care. *PloS one*. 2013;8(12):e81845.
47. **Larsen MD**, Cars T, Hallas J. A MiniReview of the use of hospital-based databases in observational inpatient studies of drugs. *Basic Clin Pharmacol Toxicol*. 2013;112(1):13-8.
48. **Larsen MD**, Nielsen LP, Jeffery L, Staehr ME. [Medication errors on hospital admission]. *Ugeskrift for laeger*. 2006;168(35):2887-90.
49. Simonsen HT, **Larsen MD**, Nielsen MW, Adersen A, Olsen CE, Strasberg D, et al. Methylendioxy- and methoxyflavones from *Melicope coodeana* syn. *Euodia simplex*. *Phytochemistry*. 2002;60(8):817-20.

SCIENTIFIC EVALUATION

For the Faculty of Pharmacy, Oslo University. Second opponent of the evaluation committee of PhD dissertation. Lene Maria Sundbakk, Nonadherence to and discontinuation of chronic psychotropic medications in pregnancy: prevalence and implications for mother and infants. June 2023

Leader of the public defence, Faculty of Medicine and Health Sciences, NTNU Chairman of the evaluation committee of PhD dissertation. Ivana Bojanic, Depression and anxiety in cardiovascular diseases and diabetes: Prevalence trends and drug treatments 1995-2019. April 2023

Member of expert committee for academic evaluation of application for Associate Professor position at OsloMet 2021

Leader of the public defence, Faculty of Medicine and Health Sciences, NTNU 18 Dec. 2020: Kristensen AK, "Quality of life in patients with advanced non-small-cell lung cancer"

Since 2014 acted as reviewer of scientific papers for different international journals. Lately (since 2020):
Clinical Epidemiology 2022 (*Impact factor 4.7*)
Andrology 2021 (*Impact factor 3.2*)
Gut 2020 (*Impact factor 17.9*)
Scientific Reports 2020 (*Impact factor 4.1*)
Andrology 2021 (*Impact factor 5.4*)

ABSTRACTS AND PRESENTATIONS

I use to participate in one or two international scientific conferences yearly. Conference below is conference where I have had participated with oral presentations:

Oral presentation. ESHRE 35th Annual Meeting June 23 - 26, 2019 – European Society of Human Reproduction and Embryology in Vienna, Austria: No decreased chance of a live born child in women with epilepsy after assisted reproduction treatment: a nationwide cohort study.

Oral presentation. IUGA 43rd Annual Meeting June 27 - 30, 2018 - International Urogynecological Association in Vienna, Austria: Perioperative cardiovascular complications following urogynaecological operations. Abstract Number: A-243

Oral presentation. 10th Congress of ECCO - Inflammatory Bowel Diseases 2015
February 18-21, 2015 in Barcelona, Spain:
Use of anti-TNF- α agents in relation to first-time surgery for ulcerative colitis and Crohn's disease during childhood. Abstract Number: A-1577

Oral presentation. International Conference Pharmacoepidemiology and Therapeutic Risk Management, Montreal, Canada 2013:
The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care.

Oral presentation. International Conference Pharmacoepidemiology and Therapeutic Risk Management, Barcelona 2012:
Hospital physicians' influence on gastrointestinal protection during treatment with non-steroidal anti-inflammatory drugs and acetylsalicylic acid and the impact on prescribing in primary care.

Oral presentation. Hospital-based pharmacoepidemiology, Scandinavian Workshop for therapy bases drug statics and individual data 2012, Stockholm, Sweden:

The use of hospital-based databases in observational inpatient studies of drugs

EuroDRUG/ISPE meeting, Antwerp 2011

The use of hospital-based databases in observational inpatient studies of drugs

Invited lecture and plenary discussion. European Society Clinical Pharmacy, Conference 2010, Lyon, France: New design of clinical pharmacy internship.

Oral presentation. Scandinavian Workshop for therapy bases drug statics and individual data 2010, Oslo, Norway: Hospital-based pharmacoepidemiology

Pharmadanmark, Hospital. Chairman for organising six national meetings through 2006-2009

Oral presentation. Danish Hospital Pharmacy Meeting Autumn 2009, Svendborg, Denmark: Hospital-based pharmacoepidemiology

Lecture - panel debate. Operation Life, Danish Society for Patient Safety 2008. Frederica. Medication errors on hospital admission.

Panel debate - poster presentation. European Association Pharmaceutical Faculties Conference 2007, Madrid: New Master in Clinical Pharmacy.

FUNDING

Janssen Pharmaceuticals, 2023. DKK 932.336: Consequences of biological therapy/disease activity and long term outcomes in patients with IBD. *co-applicant*

Overlægerådets forskningsfond. Projects in Assisted reproduction treatment. 2023. DKK 70,000 kr. *co-applicant*

Aase og Ejnar Danielsens Fond. Projects in Assisted reproduction treatment. 2023. DKK 138,440 kr. *co-applicant*

Merk Medical. Projects in Assisted reproduction treatment. 2023. DKK 160,000 kr. *co-applicant*

Stiftelsen til fremme av norsk apotekfarmasi, NOK 215,000 / NOK 24,000 , Educational book in clinical pharmacy, 2022.

The Region of Southern Denmark Free Research Fund, The efficacy of assisted reproductive technology in women with anxiety and depression 2022: DKK 443,000 kr. *co-applicant*

Janssen Pharmaceuticals, 2020: DKK 475,000 kr Prognostic factor for disease Activity in Treatment with Biologi in Crohn's Disease and Ulcerative Colitis? *co-applicant*

Odense University Hospital Free Research Fund 2018: DKK 275,000. Does Disease Activity after induction Treatment with Anti-Tumor Necrosis Factor, Predict Short-Term Outcomes in Crohn's Disease and Ulcerative Colitis?

Odense University Hospital Free Research Fund 2017: DKK 100,000. Perioperative complications following urogynaecological surgery.

CCFA (Crohn's & Colitis Foundation of America) senior grad 2015-2017: DKK 2,209,942 for special research projects concerning patients with chronic inflammatory bowel diseases. *co-applicant*

Granted from Brigham and Women's Hospital (Joshua Korzenik, MD), Boston, Massachusetts 02115. Is chronic inflammatory bowel disease provoked by anti-TNF therapy? Granted to cover biostatistical analyses. DKK 55,000 *co-applicant*

The Region of Southern Denmark Free Research Fund 2015: DKK 215,000 "General Practitioners continuation and acceptance of medication changes at sectorial transitions of geriatric patients". *co-applicant*

ORGANIZATIONAL PARTICIPATION AND POLICY CHANGE EXPERIENCE

Epidemiologist, The Danish National Registry for Biological Therapy in Inflammatory Bowel Disease
Member of the steering committee 2015-2017

Statistician and datamanager, The Danish Urogynecological Database
Member of the steering committee 2014-2017

Statistician and datamanager, The Danish Liver Cancer Group Database,
Member of the steering committee 2014-2017

Pharmadanmark Hospital, Research Foundation, member of board 2014-

Chairman of the board at Rudme-Friskole 2014-2019

Member Expert panel for the EU-directive of minimum training requirements for sectoral professions.
EU European Commission on behalf of the Danish Medicine Agency. Spring 2011.

Chairman Danish Hospital Pharmacists 2005 - 2009 [Pharmadanmark, Hospital]

Pharmaceutical consultant 2004-2005

Preparation of the first law of drug for the Greenlandic Home Rule Government,
[Landstingsforordning nr. 1 af 12. maj 2005 om lægemidler]

Pharmaceutical consultant

Report: Larsen MD, Mortensen I., Rational Pharmacotherapy and Drug Distribution in
Greenland. [Rationel farmakoterapi og lægemiddeldistribution i Grønland Kystledelsen 2004].

INTERNATIONAL COLLABORATION

Research stay at, Brigham and Women's Hospital, Boston, Massachusetts and Harvard Medical School, Boston, USA. Two weeks - September 2018

POST GRADUATE COURSES

Good Clinical Practice, Level 1 and 2, KlinForsk, Norwegian University of Science and Technology,
2020-2021

Analysis of register-based cohort studies, PhD-course, 2 ECTS, Danish Institute of Public health
University of Southern Denmark, 2012

Epidemiology in register-based research, PhD-course, 6 ECTS, Danish Institute of Public health
University of Southern Denmark, 2011

Epidemiology Principles & Methods, PhD-course, 5 ECTS, Università Cattolica Del Sacro Cuore, Rome, 2011

Oral and Written Communication in Biomedicine, 3 ECTS, PhD-course, University of Southern Denmark 2009

Research Traditions in Health Sciences, 4 ECTS, PhD-course, University of Southern Denmark 2010

Medical ethic and theory of science, 3 ECTS, PhD-course, University of Southern Denmark 2009

Pharmacoepidemiology, 3.5 ECTS, Danish Clinical Intervention Research Academy, 2008

Applied Biostatistics, 3 ECTS, PhD-course, University of Southern Denmark 2008

Biostatistics Basic, 3 ECTS, PhD-course, University of Southern Denmark 2008

Teaching and administration of education - [Pedagogisk mappe]

I am employed as an associate professor at the pharmacy education at the The Department of Clinical and Molecular Medicine at NTNU. I currently organise Clinical Pharmacy and clinical including clinical stay (22,5 ECTS). My field of research is pharmacoepidemiology and clinical epidemiology. I have been co-supervisor for one Ph.D. student and currently I supervise one Ph.D. student as main supervisor

I have a background as clinical pharmacist and hospital pharmacy manager before start of my academic career. Based on this experience I was involved, as assisting head of study, in starting up a new pharmacy education at the University of Southern Denmark (SDU). This have brought me around many difference experiences of leading and administration of education and teaching at the university.

Before that, I taught at the university college in Nuuk, Greenland and had supervision of pharmacy students and pharmacy technicians. Following I was involved in post graduated coursed in hospital pharmacy when the profession was going through a transition from a production- to a clinical oriented profession.

I such have a broad experience within teaching at all levels at the university. As student myself, I started as engineer student in a project-oriented university, following I switch to the university of pharmacy which, in that time, was based on classical lectures and highly structured lab courses.

ADMINISTRATIVE TASKS CONCERNING EDUCATION

Deputy leader for education, 2021-

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences,
Norwegian University of Science and Technology, Trondheim Norway

Study Board, Master of Pharmacy, [Studieprogramrådet for master i farmasi], 2019-
Member

Advisory board of the Norwegian pharmacy educations
[Nasjonalt fagorgan for utdanning innen farmasi], 2019-
Member

Established a new pharmacy education at the University of Southern Denmark. 2007 – 2011
Assistant Head of Study Board
Course leader
Accreditation of the pharmacy education at SDU

Member Expertpanel for the EU-directive of minimum training requirements for sectoral professions.
EU European Commission on behalf of the Danish Medicine Agency. Spring 2011

ACADEMIC TEATING EXPIRENCE

Course leader at NTNU

FARM3008 Pharmaceutical practice and clinical pharmacy 22,5 ECTS 2023-

FARM3006 Advanced pharmacotherapy 15 ECTS, 2021-

FARM3007 Pharmaceutical practice and clinical pharmacy 15 ECTS 2021-22

Taught at the following courses at the pharmacy education, NTNU
FARM3001: Clinical Pharmacy and Pharmacotherapy, spring 2020

Course leader at the University of Southern Denmark
Pharmacy Internship 2008-2010
Rational pharmacotherapy 2007-2010
Health economy and health law 2007-2009
Drug Information Project / introduction to clinical pharmacy 2007-2010, 2013

Course leader / teaching: Polypharmacy 2006 - 2010
The Danish Society for Hospital Managers

Taught at the following courses at the pharmacy education, University of Southern Denmark

Rational pharmacotherapy 2010
Pharmacy Internship 2007-2010

NON-ACADEMIA TEATING EXPIRENC

Course leader/teaching: Polypharmacy 2006 – 2010 (post graduated course for pharmacist)
The Danish Society for Hospital Managers

Teaching: Patient communication, Clinical education for pharmacist, 2006, Pharmacon, Hillerød, Denmark
The Danish Society of Pharmacy (post graduated course for pharmacist)

Teaching: Pharmacology, Clinical education for pharmacist, 2006, Pharmacon, Hillerød, Denmark
The Danish Society of Pharmacy (post graduated course for pharmacist)

Course leader/teaching: Pharmacology, Nurse eudcation, 2003-2004, Center for Sundhedsuddannelser, Nuuk, Greenland

SUPERVISION OF STUDENTS

Main-supervisor for PhD fellow at NTNU: Morten Tranung, Subcutaneous Anxiolytics in Palliative Care, 2020-

Co-supervisor for PhD fellow at SDU: Ken Lund, Disease control in pediatric and adolescent patients with inflammatory bowel disease: aspects of anti-TNF- α therapy and physical activity.

Main-supervisor for two master thesis at NTNU: Epidemiological studies of Assisted fertility treatment and chonical diseases, 2023

Main-supervisor for two master thesis at NTNU: Epidemiological studies of co-medication and co-morbidity in inflammatory bowel disease, 2022

Main-supervisor for two master thesis at NTNU: Epidemiological studies of adverse drug reactions of biological therapy in inflammatory bowel disease, 2021

Supervisor for master thesis SDU: The incidence of Crohn's disease and ulcerative colitis in 1998-2013 for children <17 years old, based on nationwide Danish registry data.

Drug Information Project for pharmacy students. Supervision and examination. 2007-2010, 2013.

Supervisor for two master thesis SDU: Continuity of PPI treatment before, during and after hospitalisation with focus on changes in the drug formulary list. 2013.

Co-supervisor for two master thesis SDU: Compliance of osteoporosis drug treatment following osteoporosis patient education. 2010.

Co-supervisor for two master thesis SDU: Trends and changes of methadone use in Odense University Hospital. 2009.

Supervisor for Pharmacy Internship, KU. Hospital Pharmacy at Dronning Ingrid's Hospital Nuuk 2003 and 2004.

OTHER EXPERIENCE CONCERNING EDUCATION

Invited lecture and plenary discussion. European Society Clinical Pharmacy, Conference 2010, Lyon, France: New design of clinical pharmacy internship.

Panel debate - poster presentation. European Association Pharmaceutical Faculties Conference 2007, Madrid: New Master in Clinical Pharmacy.

EXTERNAL EXAMINER

Appointed external examiners for the Danish Medicine and Pharmacy Educations, 2017-
Approximately 2-5 examinations of master projects per year

Regular external examiner, Nord University. 2020-
Bachelor thesis

Regular external examiner, University of Copenhagen. Spring 2020-
Social Pharmacy - Method and Dissemination
Pharmaceutical Policy

POST GRADUATE COURSES (RELATED TO EDUCATION)

Uniped - pedagogical basic competence, Norwegian University of Science and Technology's program for pedagogical basic competence in higher academic teaching - 200 hours, enrolled 2020-

Educational Course design, NTNU Uniped, autumn 2022

Development of pedagogical portfolio, NTNU Uniped, autumn 2020

Evaluations and exam assessment, NTNU Uniped, autumn 2020

Ph.D. supervisor programme, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology. Autumn 2019

Course for leaders of study administration [Lederuddannelse for studieledere], Copenhagen Business School/University of Southern Denmark 2010

OTHER EXPERIENCE RELATED TO EDUCATION

Seminar and exchange of experience. Norwegian University of Science and Technology and Arctic University of Norway. December 2022

Seminar of education, Institute for Clinical and Molecular Medicine, NTNU.

Project: «Fremtidsrettet, yrkesrelevant praksisundervisning i Farmasi ved NTNU». (prosjekt nr 90406300, 2019 - 2022). Regionalt samarbeidsorgan for utdanning, forskning og innovasjon (Samarbeidsorganet) i Helse Midt-Norge. 2020-2023

Project: «Samarbeidsorganet: Styrket kvalitet, relevans og kapasitet i praksisundervisning i Farmasi ved NTNU» 2023-2024

Reorganisation of clinical practice to national model for pharmacy educations. 2021-23